This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LPGO BTA Stock Overview

Develops drugs for lipid related diseases in Sweden. More details

LPGO BTA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 60.8% per year over past 5 years

Has less than 1 year of cash runway

Does not have a meaningful market cap (SEK25M)

Makes less than USD$1m in revenue (SEK1M)

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Lipigon Pharmaceuticals AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lipigon Pharmaceuticals
Historical stock prices
Current Share Price	SEK 1.99
52 Week High	SEK 2.60
52 Week Low	SEK 1.67
Beta	0
1 Month Change	3.32%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	3.32%

Recent updates

Shareholder Returns

	LPGO BTA	SE Biotechs	SE Market
7D	-0.3%	1.4%	0.5%
1Y	n/a	-2.7%	-3.6%

Return vs Industry: Insufficient data to determine how LPGO BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how LPGO BTA performed against the Swedish Market.

Price Volatility

Is LPGO BTA's price volatile compared to industry and market?
LPGO BTA volatility
LPGO BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.8%
10% most volatile stocks in SE Market	13.7%
10% least volatile stocks in SE Market	4.2%

Stable Share Price: LPGO BTA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine LPGO BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	7	Stefan Nilsson	www.lipigon.se

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases.

Lipigon Pharmaceuticals AB (publ) Fundamentals Summary

How do Lipigon Pharmaceuticals's earnings and revenue compare to its market cap?
LPGO BTA fundamental statistics
Market cap	SEK 24.92m
Earnings (TTM)	-SEK 45.24m
Revenue (TTM)	SEK 1.42m

17.6x

P/S Ratio

-0.6x

P/E Ratio

Is LPGO BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LPGO BTA income statement (TTM)
Revenue	SEK 1.42m
Cost of Revenue	SEK 40.77m
Gross Profit	-SEK 39.35m
Other Expenses	SEK 5.89m
Earnings	-SEK 45.24m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-4.65
Gross Margin	-2,777.27%
Net Profit Margin	-3,192.94%
Debt/Equity Ratio	0.0%

How did LPGO BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/07/17 02:14
End of Day Share Price	2022/07/14 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lipigon Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Carl Ramanius	Redeye

Lipigon Pharmaceuticals OM:LPGO BTA Stock Report